Skip to content
Sign in
Geopolitics · Asia Pacific

Treasury proposes adding biotechnology to U.S. investment restrictions

A report says Treasury has proposed adding biotechnology to U.S. investment restrictions, but the available source provides no details on the proposal’s scope, affected countries or how the restrictions would work.

AI-assisted synthesis · Based on 5 outlets' reporting · Article text read from 1 of 5 outletsHow it's made

View timeline · 8 entries
5 outlets2 regionsLatest reporting 3 min readNo new reporting in 4 days
Coverage: Too few ratedL 0 · C 1 · R 1 · 3 unrated
Updat3 graphic: United States
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • The U.S. Treasury is seeking new restrictions on U.S. investment connected to China (per dimsumdaily.hk, washingtontimes.com, cryptopolitan.com).
  • The Trump administration is proposing to add biotechnology to a sensitive-technology list that would limit some U.S. investment in Chinese biotechnology companies (per dimsumdaily.hk).
  • The U.S. has already introduced related investment limits covering artificial intelligence, semiconductors and quantum computing (per dimsumdaily.hk).

The brief

The Trump administration is seeking to restrict U.S. investment in Chinese biotechnology companies, with the Treasury proposing to add biotechnology to a list of sensitive technologies, dimsumdaily.hk reported.

The proposal would put some investment activity under new limits as American drugmakers increasingly rely on China for new medicines, a development the outlet said could complicate U.S.-China financial ties. Under the draft rules, U.S. investors would have to notify the government about certain transactions involving foreign firms developing sensitive technologies.

Other transactions would be prohibited outright. The account does not identify which specific deals would fall into either category, so the proposal’s practical reach cannot be determined from the reported description alone.

The administration has already introduced related investment restrictions covering artificial intelligence, semiconductors and quantum computing, according to dimsumdaily.hk. The proposal would add biotechnology to that set of technology areas.

Fast Company’s headline also characterizes the Treasury plan as an expansion of limits on high-tech investment in countries of concern, while Cryptopolitan’s headline describes new AI and high-tech investment restrictions targeting China.

Biotechnology is the focus of dimsumdaily.hk’s account, which ties the proposed restrictions to Chinese biotech companies and to U.S. investors’ transactions with foreign firms developing sensitive technologies. The account also points to American drugmakers’ growing reliance on China for new medicines as a factor that could make financial ties more difficult.

It does not specify the companies, transactions or medicines involved. The proposal’s treatment of China-linked biotech investment is also the subject of Fierce Biotech’s headline, which says the Treasury’s proposed COINS Act restrictions include biotech but spare Big Pharma’s China licensing deals.

That headline does not provide further detail on the licensing arrangements or on how the proposed rules would distinguish them from other transactions. For Hong Kong investors, dimsumdaily.hk identifies China-linked biotech listings and cross-border licensing as areas to follow.

It says the consultation window is the near-term watchpoint and that the meaning assigned to “sensitive” would determine whether the measure acts as a narrow screen or a broader constraint on U.S. capital for mainland life-science companies. The account gives no consultation deadline or final definition.

Why it matters

  • If adopted, the proposal could require U.S. investors to report some China-linked biotech deals and bar others, limiting a source of capital and commercial connections for affected Chinese companies. U.S. investors would face new compliance costs and fewer permissible investment opportunities, while the exact reach of the rules—and which biotech activities they cover—remains unclear.

What to watch next

  • Whether the Treasury advances the proposal to add biotechnology to its sensitive-technology list.
  • How the government defines “sensitive” in the draft rules.
  • Which transactions would require notification and which would be barred outright.
  • How the proposed rules treat China-linked biotech listings and cross-border licensing deals.

How it's being covered

Coverage analysisShow details
5 source articles · 5 unique outlets
Outlet political mix: Too few rated· 1 Center · 1 Right · 3 unrated
Where the outlets are based: Unknown 60% · US/Canada 20% · Other 20%
Outlet political mix
Too few rated
Left
Center
Right
0 outlets
1 outlet
1 outlet
The marker shows coverage balance: each unique outlet counts once. 3 unrated outlets are not included.
Geography
Where the outlets covering this story are based.
5 unique outletsDominant coverage: US/Canada
How we measure coverage

How outlets' accounts compare

Updat3 does not yet have enough full reports to compare how outlets framed this story.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. The U.S. Trade Representative published findings from its Section 301 investigation into China's technology policies.
    Background · compiled and fact-checked by Updat3
  2. Congress expanded CFIUS’s authority through the Foreign Investment Risk Review Modernization Act of 2018, part of the National Defense Authorization Act signed August 13, 2018.
    Background · from our historical context
  3. The CHIPS and Science Act, signed August 9, 2022, also provided federal support for U.S. semiconductor production and research, while restricting certain recipients’ expansion of advanced semiconductor capacity in China.
    Background · from our historical context
  4. In October 2022, the Biden administration introduced sweeping export controls on advanced computing chips and semiconductor-manufacturing equipment destined for China.
    Background · from our historical context
  5. The immediate backdrop was the U.S. outbound-investment program established by President Joe Biden’s Executive Order 14105, signed August 9, 2023.
    Background · from our historical context
  6. The Treasury Department issued a proposed rule implementing Executive Order 14105.
    Background · compiled and fact-checked by Updat3
  7. The Treasury Department issued a final rule on U.S. outbound investment restrictions.
    Background · compiled and fact-checked by Updat3
  8. The Treasury Department's outbound investment rule took effect.
    Background · compiled and fact-checked by Updat3

How we got here

The immediate backdrop was the U.S. outbound-investment program established by President Joe Biden’s Executive Order 14105, signed August 9, 2023. The order directed the Treasury Department to regulate certain U.S. investments in China, Hong Kong and Macau involving semiconductors and microelectronics, quantum information technologies, and artificial intelligence.

Treasury issued a proposed rule on June 21, 2024, and a final rule on October 28, 2024; the rule took effect January 2, 2025. Congress expanded CFIUS’s authority through the Foreign Investment Risk Review Modernization Act of 2018, part of the National Defense Authorization Act signed August 13, 2018.

Original sources

1 of 5 articles · Asia · Show all

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.